Regeneron other transaction authority (OTA) award
Active Definitive Contract Awarded Last action
- Contract number
- HHSO100201700020C
- Awardee
-
Regeneron Pharmaceuticals Inc. UEI N3F9MH7E6HD6
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $278,844,172
Award facts
- Opportunity
-
- BAA16100SOL00002 Solicitation number
- Broad Agency Announcement (BAA) for the Advanced Development of Medical Countermeasures for Pandemic Influenza Award Notice · Posted Oct 1, 2015
- Contract value 78% obligated
-
- $278,844,171.83 Current, with exercised options
- $359,611,757.83 Potential, with all options
- Completion date 91% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Sharing
- Place of performance
- Sleepy Hollow, NY 10591, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$766,396 | |
| Other Administrative Action | -$331,708,160 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $326,475,498 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $53,517,946 | |
| Change Order | $85,094,597 | |
| Funding Only Action | $9,247,916 | |
| Change Order | $92,984,806 | |
| Other Administrative Action | $0 | |
| Change Order | $5,751,859 | |
| Change Order | $19,552,893 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $18,693,213 |
Show all 18
About this award
The Office of the Assistant Secretary for Preparedness and Response awarded a definitive contract to Regeneron Pharmaceuticals Inc. for novel antibodies against influenza virus, emerging, re-emerging, and pre-emerging pathogens under Other Transaction Authority on September 21, 2017, with a ceiling value of $359.611 million and cost-sharing pricing.
Place of performance is Sleepy Hollow, NY. The contract has been extended; the ultimate completion date is September 25, 2027. A recent modification de-obligated funds on Option 2 and extended the period of performance for CLINs 0002 and 0003 to September 25, 2027, adding final indirect rates and an updated statement of work.
In fiscal year 2024, the contract invoiced $21.8 million across 10.2 FTEs and 21,225 contractor hours, with a derived government-paid hourly rate of $1,026.31. Regeneron self-performed all reported hours with no subcontractors.
Quick answers
Who was awarded contract HHSO100201700020C?
HHSO100201700020C was awarded to Regeneron Pharmaceuticals Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 21, 2017.
How much is contract HHSO100201700020C worth?
The government has obligated $278,844,172 on HHSO100201700020C. Its potential value, with all options, is $359,611,758.
Was contract HHSO100201700020C competed?
The extent of competition for HHSO100201700020C was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award